portfolio
Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution
Alkermes; Avadel Pharmaceuticals; acquisition; LUMRYZ; narcolepsy; sleep medicine; strategic portfolio; biopharmaceuticals; rare disease; deal premium
Sanofi Injects $625M Into Biotech Investment Arm to Accelerate Innovation
Sanofi; Sanofi Ventures; biotech investment; $625M cash infusion; digital health; immunology; rare diseases; neurology; venture capital; cell/gene therapy; portfolio expansion
Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field
Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit
Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance
Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics Amid Cost-Cutting Measures
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, cost-cutting, strategic productivity initiative, portfolio prioritization
ALK-Abell Acquires Epinephrine Nasal Spray for $145 Million
ALK-Abell, Epinephrine Nasal Spray, Acquisition, Pharmaceutical Portfolio
Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets
Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects
Alpha-9 Radios Secures $175M Funding for RLT Portfolio Advancement
Alpha-9 radios, $175M funding, RLT portfolio, radiopharmaceuticals, biotech investment
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin
Syncona Expands Portfolio with Investments in iOnctura and Yellowstone, Two Cancer-Focused Biotechs
Syncona, iOnctura, Yellowstone, cancer biotechs, portfolio expansion, investment, biotechnology